Results 331 to 340 of about 3,353,866 (404)

From Lab to Market: Paper‐Based CRISPR Diagnostics and Commercialization Pathways

Advanced Sensor Research, Volume 4, Issue 10, October 2025.
Paper‐based CRISPR diagnostics represents one of the most widely commercialized CRISPR assay technologies, yet challenges remain for broader point‐of‐care use. Abstract The global health landscape is continually challenged by infectious diseases that can swiftly escalate into pandemics, underscoring the need for rapid, accurate, and cost‐effective ...
Selen Dalgan, Qingshan Wei
wiley   +1 more source

API5 Phosphorylation Promotes Antiviral Immunity by Inhibiting Degradation of Cytosolic RNA Sensor RLRs

Advanced Science, Volume 12, Issue 37, October 6, 2025.
Ubiquitin‐mediated selective autophagy plays a critical role in antiviral innate immunity. The study shows that upon RNA virus infection, cytoplasmic API5 undergoes SRPK1‐dependent phosphorylation at S464, which in turn suppresses p62 K141 ubiquitination‐dependent autophagy.
Tingjuan Deng, Jianan Xu, Linglong Qin, Xingbo Wang, Chenhe Lu, Yanming Huang, Da Liu, Yan Yan, Weiren Dong, Pinglong Xu, Jiyong Zhou   +10 more
wiley   +1 more source

One‐Pot Isothermal Nucleic Acid Amplification Assisted CRISPR/Cas Detection Technology: Challenges, Strategies, and Perspectives

Advanced Science, Volume 12, Issue 37, October 6, 2025.
This review combines the current status of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat)‐based molecular diagnostic technology to expound the necessity and challenges faced in promoting the development of one‐pot detection. Besides, the focus is on a comprehensive summary and incisive analysis of emerging strategies for one‐pot ...
Hongyan Liu, Hui Yin, Leshan Xiu, Wenyu Wu, Qinqin Hu, Yingchen Xia, Brianna Garcia, Shamsuttiyeba Shifa, Hui Chen, Min Li, Kun Yin   +10 more
wiley   +1 more source

NamiRNA‐Enhancer Network: The Changing Era Challenge and Chance of miRNA

Advanced Science, Volume 12, Issue 39, October 20, 2025.
MiRNAs (miRNAs) regulate diverse biological processes across species. Unlike canonical miRNA‐mediated gene repression, Nuclear Activating miRNAs (NamiRNAs) can efficiently upregulate gene expression by targeting enhancers. This review systematically summarizes recent advances in NamiRNA research, elucidates the theory of NamiRNA‐Enhancer‐mediated Gene ...
Lu Chen, Ying Liang, Hongyan Wei, Mengxing Liu, Jin Wu, Wei Li, Wenxuan Li, Yuxiao Jin, Yinshan Li, Wei Zhao, Min Xiao, Kaicheng Zhou, Shuai Yang, Wenqiang Yu   +13 more
wiley   +1 more source

Penile cancer in French Guiana: Epidemiology, histopathology and clinical aspects

BJUI Compass, Volume 6, Issue 10, October 2025.
Abstract Objectives To study the characteristics of penile cancer in French Guiana (FG)— a French overseas department in South America. Indeed, penile cancer is a rare malignancy with significant geographic and socioeconomic disparities. While its epidemiology is well‐documented in mainland France, data from FG remain limited.
Khalil Chalhoub, Bawa Nonoa, Vincent Molinier, Vincent Ravery   +3 more
wiley   +1 more source

Specific Marker Gene Analysis for Primary Central Nervous System Lymphoma Based on Methylation Difference and Development of Detection Primers

Brain and Behavior, Volume 15, Issue 10, October 2025.
Promoter hypermethylation of the RHEB gene is identified as a specific biomarker for Primary Central Nervous System Lymphoma (PCNSL). This study develops methylation‐specific primers, demonstrating their power to distinguish PCNSL from other CNS diseases via a novel plasma‐based detection method.
Feng Yan, Yaming Wang, Xiaotong Fan, Penghu Wei, Yongzhi Shan   +4 more
wiley   +1 more source

LAG3 as a Tumor Suppressor and Immune Regulator in Cervical Cancer: From Functional Validation to Therapeutic Strategy

Cancer Medicine, Volume 14, Issue 19, October 2025.
Studies have found that the molecular typing of pyroptostic‐related genes (PRGs) in cervical cancer can predict prognosis, and the GNAZ/LAG3/IL1B/CA2/SPRR3 risk scoring model has been constructed. Experiments have confirmed that LAG3 inhibits tumor progression by regulating Treg and CD8+ T cells, providing a new target for immunotherapy.
Shijie Yao, Siming Chen, Shimeng Wan, Anjin Wang, Ziyan Liang, Xuelian Liu, Yang Gao, Hongbing Cai   +7 more
wiley   +1 more source

Advancing equity: the urgent need to include trans and gender diverse people in cervical cancer prevention in Australia

Medical Journal of Australia, Volume 223, Issue 7, Page 338-342, October 2025.
Kade Booth, Jamie Bryant, Shiva Chandra, Cristyn Davies, Lucille Kerr, Katie Wynne, Melissa A Carlson, Barrie Shannon, Sav Zwickl, Tamara Butler, Lisa J Whop   +10 more
wiley   +1 more source

Current status and future perspectives of multi‐modal bacteria‐based cancer therapies

Clinical and Translational Medicine, Volume 15, Issue 10, October 2025.
Bacteria exhibit inherent tumour‐targeting capabilities, particularly thriving in hypoxic tumour microenvironments (TMEs) and activating potent anti‐tumour immune responses through pathogen‐associated molecular patterns (PAMPs) and immunomodulation.
Shuai Fan, Siyu Zhu, Wenyu Wang, Yuetong Liu, Yutong Zhou, Hao Li, Bofeng Liu, Qin Xia, Lili Huang, Lei Dong   +9 more
wiley   +1 more source

p‐Cymene Targets Multiple Oncogenic Pathways in Hepatocellular Carcinoma: Insights From Network Pharmacology and In Vitro Studies

Food Science &Nutrition, Volume 13, Issue 10, October 2025.
p‐Cymene exhibited a strong affinity for key hepatocellular carcinoma (HCC) targets and induced dose‐dependent cytotoxicity in HepG2 cells while enhancing antioxidant defense mechanisms. The treatment significantly modulated apoptotic and angiogenic markers, notably increasing Caspase‐3 and p53, and suppressing BCL2 and VEGF expression.
Nadia Anwar, Muhammad Nasir Hayat Malik, Muhammad Atif, Abdullah R. Alanzi, Hattan A. Alharbi, Waqas Younis, Munawar Abbas, Gideon F. B. Solre   +7 more
wiley   +1 more source